WHO prequalifies the first vaccine against mpox
WEBSep 13, 2024 · Available data shows that a single-dose MVA-BN vaccine given before exposure has an estimated 76% effectiveness in protecting people against mpox, with the 2-dose schedule achieving an estimated 82% effectiveness. Vaccination after exposure is less effective than pre-exposure vaccination.
Bavarian Nordic Awarded USD 63 Million from the U.S.
WEB7 hours ago · MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS ®), Canada (marketed as ...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for
WEB5 days ago · Bavarian Nordic is preparing for a clinical trial (NCT06549530) to assess the immunogenicity and safety of MVA-BN in children 2-12 years of age, aiming to further extend the indication of the ...
Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox …
WEBJun 16, 2023 · The third-generation smallpox vaccine, modified vaccinia Ankara–Bavarian Nordic (MVA-BN), a highly attenuated strain of the poxvirus chorioallantois vaccinia virus Ankara, is licensed for both pre-exposure and post-exposure mpox prophylaxis. 1 MVA-BN has been used extensively as part of the global public health response, and new cases have ...
The road to approved vaccines for respiratory syncytial virus
WEBSep 25, 2023 · The MVA-BN-RSV vaccine candidate uses a nonreplicating modified vaccinia Ankara (MVA) virus to deliver multiple RSV antigens (F, N, M2–1, and G from both A and B subtypes) 102.
WHO approves first mpox vaccine to boost access in Africa - UN News
WEBSep 13, 2024 · The MVA-BN vaccine from the Danish pharmaceutical company Bavarian Nordic was prequalified by the WHO on Friday and has already been approved in Europe and the United States, for use by adults....
News | Bavarian Nordic
WEBApr 11, 2023 · Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial. Pivotal Phase 3 trial of MVA-BN ® RSV has accrued enough cases required for efficacy analysis; Topline results expected around mid-2023
Effectiveness of modified vaccinia Ankara-Bavarian Nordic …
WEBSep 11, 2024 · In an emulated target trial to reduce biases, the effectiveness of a single dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine against mpox infection was 58% (95% confidence interval 31% to 75%)—a finding that was robust to further sensitivity analysis for residual confounding.
A prospective national cohort evaluating ring MVA vaccination as …
WEBJul 13, 2022 · Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) is a third-generation live vaccine that is non-replicative in humans. It was authorized in 2013 by the European Medicines Agency, under...
A call for global solidarity and rapid action to control mpox
WEB3 days ago · Access to smallpox-based vaccines and antiviral drugs for compassionate use is a substantial challenge in Africa. WHO's regulatory delays have slowed vaccine distribution to hard-hit countries such as DR Congo, 6 which received 99 100 doses of the MVA-BN vaccine on September 5, followed by 100 900 more doses on September 7, totalling 200 000 doses, far short of the 10 million needed to control ...